-
Mashup Score: 9Online Event - 3 month(s) ago
Given the urgent need to shorten timelines and lower costs for biologics such as monoclonals (specially biosimilars) as well as address the demand for complex proteins such as bispecific antibodies, the biopharma industry is re-evaluating traditional manufacturing methods that have been a staple of drug development for decades. Developing new therapy modalities requires sustainable strategies and technologies that maximize production. To tackle the limitations with existing bioprocesses, manufacturers
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 7Online Event - 3 month(s) ago
Given the urgent need to shorten timelines and lower costs for biologics such as monoclonals (specially biosimilars) as well as address the demand for complex proteins such as bispecific antibodies, the biopharma industry is re-evaluating traditional manufacturing methods that have been a staple of drug development for decades. Developing new therapy modalities requires sustainable strategies and technologies that maximize production. To tackle the limitations with existing bioprocesses, manufacturers
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
MARK YOU CALENDAR! On 10/17, our expert speakers will share their journey of implementing intensified technologies and its potential to improve the efficiency and cost-effectiveness of biologics manufacturing. REGISTER: https://t.co/Sxdjg4NtqR @SartoriusGlobal #Bioprocessing https://t.co/RgVbXlLePv
-
-
Mashup Score: 4Online Event - 3 month(s) ago
Over the last few years, RNA-encapsulated lipid nanoparticles (RNA-LNPs) have emerged as a new drug modality with the potential to change the pace of biopharmaceutical innovation. GMP manufacturing of RNA-LNPs is both labor intensive and resource-heavy, requiring stringent protocols and environmental controls to ensure RNA integrity and consistency, as well as robust quality control and documentation. As RNA-LNPs mature and expand to new applications and diverse scales, the manufacturing process poses
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
LAST CHANCE! TODAY, David Sokolowski and Ingram Vargas will share strategies for successfully navigating evolving manufacturing workflows, processes, and technologies for RNA vaccines and therapies. REGISTER: https://t.co/jmd8aNxI3g @precisionnano #Bioprocessing https://t.co/8D0FhWT4rk
-
-
Mashup Score: 4Online Event - 3 month(s) ago
Over the last few years, RNA-encapsulated lipid nanoparticles (RNA-LNPs) have emerged as a new drug modality with the potential to change the pace of biopharmaceutical innovation. GMP manufacturing of RNA-LNPs is both labor intensive and resource-heavy, requiring stringent protocols and environmental controls to ensure RNA integrity and consistency, as well as robust quality control and documentation. As RNA-LNPs mature and expand to new applications and diverse scales, the manufacturing process poses
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
MARK YOUR CALENDAR! On 10/8, David Sokolowski and Ingram Vargas will share strategies for successfully navigating evolving manufacturing workflows, processes, and technologies for RNA vaccines and therapies. REGISTER: https://t.co/XFX2XOXD0p @precisionnano #Bioprocessing https://t.co/DbwWUz8se3
-
-
Mashup Score: 5Online Event - 3 month(s) ago
Over the last few years, RNA-encapsulated lipid nanoparticles (RNA-LNPs) have emerged as a new drug modality with the potential to change the pace of biopharmaceutical innovation. GMP manufacturing of RNA-LNPs is both labor intensive and resource-heavy, requiring stringent protocols and environmental controls to ensure RNA integrity and consistency, as well as robust quality control and documentation. As RNA-LNPs mature and expand to new applications and diverse scales, the manufacturing process poses
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
NEW WEBINAR! On 10/8, David Sokolowski and Ingram Vargas will share strategies for successfully navigating evolving manufacturing workflows, processes, and technologies for RNA vaccines and therapies. REGISTER: https://t.co/nrg9CDzy97 @precisionnano #Bioprocessing https://t.co/ZTYI78aVLz
-
-
Mashup Score: 6Online Event - 5 month(s) ago
Reliability is paramount when developing targeted cell and gene therapies (CGTs). The current need to control end-product costs will continue in the future as advanced therapies mature and continue to become more widely used. The challenges and costs associated with developing and securing approval for a therapy can reach hundreds of thousands of dollars per dose. Making improvements to the CGT manufacturing process by adopting single-use technologies such as sterile connectors for small-batch processes
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
LAST CHANCE! TODAY, Troy Ostreng will discuss CPC’s suite of connector solutions for addressing sterility, chemical compatibility, and ultra-low temperature challenges in the CGT development process. REGISTER: https://t.co/UBcidpV6Hh @ColderProducts #Bioprocessing https://t.co/C1EsZLOtso
-
-
Mashup Score: 6Online Event - 5 month(s) ago
Reliability is paramount when developing targeted cell and gene therapies (CGTs). The current need to control end-product costs will continue in the future as advanced therapies mature and continue to become more widely used. The challenges and costs associated with developing and securing approval for a therapy can reach hundreds of thousands of dollars per dose. Making improvements to the CGT manufacturing process by adopting single-use technologies such as sterile connectors for small-batch processes
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
DON'T MISS OUT! On 8/15, Troy Ostreng will discuss CPC’s suite of connector solutions for addressing sterility, chemical compatibility, and ultra-low temperature challenges in the CGT development process. REGISTER: https://t.co/2z2u2tAFiS @ColderProducts #Bioprocessing https://t.co/cssUx8OfPy
-
-
Mashup Score: 4Online Event - 5 month(s) ago
Reliability is paramount when developing targeted cell and gene therapies (CGTs). The current need to control end-product costs will continue in the future as advanced therapies mature and continue to become more widely used. The challenges and costs associated with developing and securing approval for a therapy can reach hundreds of thousands of dollars per dose. Making improvements to the CGT manufacturing process by adopting single-use technologies such as sterile connectors for small-batch processes
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
NEW WEBINAR! On 8/15, Troy Ostreng will discuss CPC’s suite of connector solutions for addressing sterility, chemical compatibility, and ultra-low temperature challenges in the CGT development process. REGISTER: https://t.co/xjCv9Z8QNB @ColderProducts #Bioprocessing https://t.co/fghFjQNnDB
-
-
Mashup Score: 5Online Event - 5 month(s) ago
Novel or next-generation biologics such as bispecific antibodies (bsAbs) and fusion proteins present unique development and manufacturing process challenges due to complex formats, suboptimal stability, product aggregation, or low productivity. These issues impact product quality and consistency, as well as the ability to develop efficient and scalable processes. Successfully addressing these challenges while reducing the cost of goods (COGs) requires the strategic utilization of advanced technologies,
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
NEW WEBINAR! On 7/29, our speakers will present WuXi Biologics’ suite of advanced solutions for overcoming obstacles associated with the development and manufacturing of complex biologics. REGISTER: https://t.co/Dakqp6Op7G @WuXiBiologics #Bioprocessing https://t.co/SBAbaAiaAr
-
-
Mashup Score: 5Online Event - 5 month(s) ago
Novel or next-generation biologics such as bispecific antibodies (bsAbs) and fusion proteins present unique development and manufacturing process challenges due to complex formats, suboptimal stability, product aggregation, or low productivity. These issues impact product quality and consistency, as well as the ability to develop efficient and scalable processes. Successfully addressing these challenges while reducing the cost of goods (COGs) requires the strategic utilization of advanced technologies,
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
NEW WEBINAR! On 7/29, our speakers will present WuXi Biologics’ suite of advanced solutions for overcoming obstacles associated with the development and manufacturing of complex biologics. REGISTER: https://t.co/Dakqp6Op7G @WuXiBiologics #Bioprocessing https://t.co/SBAbaAiaAr
-
LAST CHANCE! TODAY, our expert speakers will share their journey of implementing intensified technologies and its potential to improve the efficiency and cost-effectiveness of biologics manufacturing. REGISTER: https://t.co/WDIuM7dcIN @SartoriusGlobal #Bioprocessing https://t.co/DVVlQkIL8y